Eli Lilly And Stock Piotroski F Score

LLY Stock  USD 777.96  0.22  0.03%   
This module uses fundamental data of Eli Lilly to approximate its Piotroski F score. Eli Lilly F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Eli Lilly And. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Eli Lilly financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Eli Lilly Altman Z Score, Eli Lilly Correlation, Eli Lilly Valuation, as well as analyze Eli Lilly Alpha and Beta and Eli Lilly Hype Analysis.
  
At this time, Eli Lilly's Short and Long Term Debt Total is fairly stable compared to the past year. Net Debt is likely to rise to about 23.5 B in 2024, whereas Long Term Debt Total is likely to drop slightly above 11.6 B in 2024. At this time, Eli Lilly's Company Equity Multiplier is fairly stable compared to the past year. Long Term Debt To Capitalization is likely to rise to 0.66 in 2024, whereas Short Term Coverage Ratios is likely to drop 0.58 in 2024.
At this time, it appears that Eli Lilly's Piotroski F Score is Healthy. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
6.0
Piotroski F Score - Healthy
Current Return On Assets

Positive

Focus
Change in Return on Assets

Increased

Focus
Cash Flow Return on Assets

Positive

Focus
Current Quality of Earnings (accrual)

Decreasing

Focus
Asset Turnover Growth

Increase

Focus
Current Ratio Change

Increase

Focus
Long Term Debt Over Assets Change

Higher Leverage

Focus
Change In Outstending Shares

Decrease

Focus
Change in Gross Margin

No Change

Focus

Eli Lilly Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Eli Lilly is to make sure Eli is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Eli Lilly's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Eli Lilly's financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.70.5331
Significantly Up
Slightly volatile
Gross Profit Margin0.620.8073
Way Down
Pretty Stable
Total Current Liabilities28.7 B27.3 B
Sufficiently Up
Slightly volatile
Non Current Liabilities Total27.1 B25.8 B
Sufficiently Up
Slightly volatile
Total Assets67.2 B64 B
Sufficiently Up
Slightly volatile
Total Current Assets27 B25.7 B
Sufficiently Up
Slightly volatile
Total Cash From Operating Activities4.3 B4.2 B
Fairly Up
Slightly volatile

Eli Lilly And F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Eli Lilly's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Eli Lilly in a much-optimized way.

About Eli Lilly Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Common Stock Shares Outstanding

868.35 Million

At this time, Eli Lilly's Common Stock Shares Outstanding is fairly stable compared to the past year.

Eli Lilly ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Eli Lilly's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Eli Lilly's managers, analysts, and investors.
Environment Score
Governance Score
Social Score

About Eli Lilly Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Eli Lilly And's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eli Lilly using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eli Lilly And based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. Eli Lilly operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 35000 people.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Eli Lilly And offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eli Lilly's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eli Lilly And Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eli Lilly And Stock:
Check out Eli Lilly Altman Z Score, Eli Lilly Correlation, Eli Lilly Valuation, as well as analyze Eli Lilly Alpha and Beta and Eli Lilly Hype Analysis.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Eli Stock analysis

When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
Commodity Directory
Find actively traded commodities issued by global exchanges
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Is Eli Lilly's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eli Lilly. If investors know Eli will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eli Lilly listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.13
Dividend Share
4.52
Earnings Share
5.81
Revenue Per Share
37.908
Quarterly Revenue Growth
0.281
The market value of Eli Lilly And is measured differently than its book value, which is the value of Eli that is recorded on the company's balance sheet. Investors also form their own opinion of Eli Lilly's value that differs from its market value or its book value, called intrinsic value, which is Eli Lilly's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eli Lilly's market value can be influenced by many factors that don't directly affect Eli Lilly's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.